微創醫療(00853.HK)指業務穩定增長 料明年重點產品可獲准上市
微創醫療(00853.HK)公布,關注到近期公司股份價格出現較大波動,集團目前主要業務保持穩定增長,董事和管理層對集團發展充滿信心。
公司指出,自年初至今,集團及聯營已累計有33款產品獲得國家藥監局(NMPA)頒發的三類醫療器械註冊證,或完成重要註冊變更。在海外,今年以來集團及聯營公司共有15款產品獲得美國食品藥監局(FDA)核准,10款產品獲得歐盟CE認證,其中亦包含諸多重磅產品。
此外,基於現有產品研發及註冊進度,集團預計可在明年左右獲准上市的重點產品如冠脈旋磨系統、冠脈衝擊波球囊導管系統、ENO系列磁共振相容起搏器、第三代TAVI產品等,有望構成新的增長引擎。集團將持續高效推進已上市產品在海內外市場的拓展及推廣,通過高價值的全球產品佈局,充分發揮平台化協同效應。
微創醫療現報8.26元,升2.99%,成交576.7萬股,涉資4,724.42萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.